EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy

Jiayu Liu, Wenxia Shao, Qing Ye

eBioMedicine · 2026-12 · 134 · 106540

DOI: 10.1016/j.ebiom.2026.106540 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift eBioMedicine, 2026-12. Verfasst von Jiayu Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Centre for Children and Ad…. Die Arbeit nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cellular senescence acts as a core driver of chronic diseases and tissue degeneration. Conventional small-molecule senolytics face critical limitations including poor target specificity and off-target toxicity when eliminating heterogeneous senescent cell populations. This review systematically discusses senescence-targeted engineered chimeric antigen receptor (CAR)-T immunotherapy, which achieves targeted clearance of pathological senescent cells by recognising specific surface markers. It summarises target-antigen evaluation frameworks, analyzes aged immunosuppressive microenvironment barriers and corresponding engineering strategies, and outlines composite efficacy assessment systems and tiered biomarker-monitoring workflows. Key translational bottlenecks such as imperfect antigen specificity and immune escape are also addressed. Preclinical studies verify organ function restoration and healthspan extension, while clinical evidence remains limited. Future integration of CAR-T technology with smart nanocarriers, synthetic biology and artificial intelligence will promote its clinical translation for senescence-associated disorders.

Schlagwörter

Stichwörter der Autor:innen

CAR-T-cell therapyEngineered senolytic immunotherapyFibrosis treatmentImmune microenvironmentSenescence biomarkersSenescent cell heterogeneity

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Centre for Children and Adolescents' Health and Diseases, Hangzhou, China.
  • Department of Clinical Laboratory, Affiliated Hangzhou First People's Hospital, Hangzhou, China.
  • Department of Clinical Laboratory, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Centre for Children and Adolescents' Health and Diseases, Hangzhou, China. Electronic address: q…

Zitieren

APA

Liu, J., Shao, W., & Ye, Q. (2026). Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy. eBioMedicine, 134, 106540. https://doi.org/10.1016/j.ebiom.2026.106540

Vancouver

Liu J, Shao W, Ye Q. Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy. eBioMedicine. 2026;134:106540. doi:10.1016/j.ebiom.2026.106540

BibTeX
@article{Liu2026,
  author = {Liu, Jiayu and Shao, Wenxia and Ye, Qing},
  title = {Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy},
  journal = {eBioMedicine},
  year = {2026},
  volume = {134},
  pages = {106540},
  doi = {10.1016/j.ebiom.2026.106540}
}
Kostenlos starten →